(Q34196622)

31 July 2017

1 reference

title

Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust (English)

1 reference

31 July 2017

Davidson MH

1

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

61

1 reference

31 July 2017

2

1 reference

31 July 2017

197-206

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200161020-00005

31 July 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: implications for the biophysical role of highly unsaturated fatty acids.

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Assessing the observed relationship between low cholesterol and violence-related mortality. Implications for suicide risk.

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

Lovastatin and rhabdomyolysis

1 reference

12 December 2020

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

12 December 2020

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

12 December 2020

Cholesterol and violent behavior

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program

1 reference

12 December 2020

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors

1 reference

12 December 2020

Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan

1 reference

12 December 2020

Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV

1 reference

12 December 2020

Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs

1 reference

12 December 2020

Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro

1 reference

12 December 2020

State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Management of dyslipidemia in adults.

1 reference

12 December 2020

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

12 December 2020

Epidemiology of stroke among Japanese men in Hawaii during 24 years of follow-up: the Honolulu Heart Program.

1 reference

12 December 2020

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

12 December 2020

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

12 December 2020

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

12 December 2020

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

10.2165/00003495-200161020-00005

Identifiers

DOI

1 reference

PubMed ID

11270938

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11270938